Recent News

AffyImmune Therapeutics Adds Serial Entrepreneur Robert Forrester to Board of Directors

NATICK, Mass. (SEPTEMBER 29, 2022) – AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track platform to develop CAR T cells for the treatment of solid cancers, announced today that serial biotech entrepreneur Robert Forrester has been appointed to its Board of Directors. Mr. Forrester’s biotech experience [...]

AffyImmune Therapeutics Announces Hiring of Dr. Sonal Gupta as Senior Vice President and Head of Clinical Development

NATICK, Mass. (APRIL 25, 2022) – AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today the addition of Sonal Gupta, MD, PhD to its senior leadership team as Senior Vice President and Head of Clinical Development. “As immuno-oncology [...]

AffyImmune Therapeutics to Present Initial Clinical Results at Upcoming CAR-TCR Summit

NATICK, Mass. (AUGUST 19, 2021) – AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today that scientific co-founder Moonsoo Jin will present twice at Hanson Wade’s 6<sup>th</sup> CAR-TCR Summit being held virtually August 30 – September 2. [...]

AffyImmune Therapeutics Announces Hiring of Matt Britz as Senior Vice President of Business Development

NATICK, Mass., June 21, 2021 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR-T cells against solid cancers, announced today the addition of Matt Britz to its management team as its Senior Vice President of Business Development. "Matt brings deep industry experience, [...]

Events

There are no events at this time.